Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) has announced that it has received a Notice of Allowance (NOA) from the United States Patent and Trademark Office (USPTO), protecting its heart drugs— clinical-stage CardioRX and preclinical-stage CRD-38—until October 2040.
Once issued, the new patent will establish broad intellectual property (IP) protection for the use of CardiolRx and CRD-38 in the treatment or prevention of an extensive range of cardiac conditions, including heart failure, myocarditis, acute pericarditis, inflammatory cardiomyopathy, cardiac toxicity from anti-cancer therapies, and atherosclerosis.
This allowance fortifies the company’s global IP portfolio, adding to granted and pending patent applications in Europe, Japan, Canada, Australia, and China.
In a statement, David Elsley, president and CEO of Cardiol, commented, “This important milestone extends our IP protection to the world’s largest pharmaceutical market. Together with our U.S. Orphan Drug Designation for pericarditis, this new patent allowance fortifies Cardiol’s market position and IP portfolio, providing broad protection across a diverse range of heart diseases characterized by inflammation and fibrosis. This expanded exclusivity coverage also reinforces the long-term value of our pipeline as we advance late-stage clinical programs in recurrent pericarditis and acute myocarditis-inflammatory heart diseases with significant unmet medical needs-and as we prepare to initiate first-in-human clinical evaluation of CRD-38, our novel subcutaneously administered therapy for inflammatory heart disease, including heart failure. By securing this protection through late 2040, we are solidifying a strong foundation to support our global clinical and commercial strategy.”
Dr. Andrew Hamer, CMO and Head of R&D of Cardiol, added, “This patent allowance comes at an opportune time, adding extensive intellectual property protection in new areas of heart disease that have been identified for potential research expansion based on the recently reported topline ARCHER findings. We now look forward to presenting the comprehensive data from ARCHER-our randomized, double-blind, placebo-controlled Phase II trial of CardiolRx in acute myocarditis-at the upcoming European Society of Cardiology Annual Meeting in Trieste, Italy, on November 29, and to providing insights into potential new development opportunities in myocarditis, as well as the positive implications for our CRD-38 program in heart failure. We also look forward to providing an update on our pivotal Phase III MAVERIC trial in recurrent pericarditis, as patient enrollment continues to accelerate across leading cardiovascular research centers in the U.S.”
